This clinical trial is focused on studying the effects of a medication called Ulotaront on adults with Generalized Anxiety Disorder (GAD). Generalized Anxiety Disorder is a condition characterized by excessive and persistent worry about various aspects of life. The medication being tested, Ulotaront, is taken in the form of a tablet and is also known by its code name SEP-363856. The study will compare the effects of Ulotaront with a placebo to determine its effectiveness and safety in treating GAD.

The purpose of the study is to evaluate how well Ulotaront works in reducing anxiety symptoms in adults with GAD. Participants in the study will receive either Ulotaront or a placebo, and the doses of Ulotaront will range from 50 to 75 milligrams per day. The study will be conducted over a period of time, allowing researchers to observe changes in anxiety levels and any potential side effects. The study aims to provide valuable information on the potential benefits of Ulotaront for individuals with Generalized Anxiety Disorder.

Throughout the study, participants will be monitored to assess changes in their anxiety symptoms using a tool called the Hamilton Anxiety Rating Scale. This scale helps measure the severity of anxiety symptoms. The study will also look at overall impressions of the participants’ condition using another tool called the Clinical Global Impression-Severity score. By the end of the study, researchers hope to gather important data on the effectiveness and safety of Ulotaront in treating Generalized Anxiety Disorder.